Spotlight on Cancer Centers

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 5
Volume 17
Issue 5

The recently opened Institute of Cancer “Octavio Frias de Oliveira,” in Brazil’s capital of São Paulo, is a state institution that will care for cancer patients from São Paulo as well as neighboring states, according to information provided by ONI Editorial Advisory Board member Paulo Hoff, MD, of The Medical School of the University of São Paulo.

The recently opened Institute of Cancer “Octavio Frias de Oliveira,” in Brazil’s capital of So Paulo, is a state institution that will care for cancer patients from So Paulo as well as neighboring states, according to information provided by ONI Editorial Advisory Board member Paulo Hoff, MD, of The Medical School of the University of So Paulo.

The new cancer center is named after Octavio Frias de Oliveira, who built a media empire in Brazil and was publisher of Folha de So Paulo, Brazil’s largest newpaper. Mr. Frias died last year at age 94.

Managed by medical school


With 580 beds, the new hospital will be managed by The Medical School of the University of So Paulo, the premier medical school in Brazil.

The Institute will focus on medical care, education, and research. The objective is to position the Institute as one of the main research centers in the world. 

When operating at full capacity, it is estimated that the Institute will deliver care to approximately 16,000 new patients every year. It occupies a 28-floor building, with 540,000 square feet dedicated to cancer care and research.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Related Content